Atlas market file · Equity · United States
Organon & Co.OGN
- Last close
- 13.6
- Change
- +0.37%
- 96-bar range
- 5.69 – 13.61
- As of
- 7 Aug 2026
Organon & Co. is a pharmaceutical preparations issuer listed as OGN on NYSE. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
- Identity
- Nasdaq Trader
- Chart rail
- TradingView
- File state
- Public profile
OGN
Equity · evidence first
Static Daily candlestick snapshot from the approved cache, drawn on a labelled price axis: green bodies closed up, red closed down, wicks span each bar's high-to-low range. The live TradingView link stays available; the public profile never embeds a widget that can render the wrong symbol.
▮ up candle ▮ down candle
Weekly outlook: the last 104 weekly closes (-39.18% over the window).
Source rail: Yahoo Finance chart API (OGN). This dated snapshot is the crawlable Atlas reference.
Live market viewTradingView · provider feed Open view ->
Open the attributed TradingView market view for OGN. The dated Atlas snapshot above remains the crawlable reference; exchange data in this panel may be live or delayed as labelled by TradingView.
OGN public profile
Pharmaceutical preparations issuer. Organon & Co. is connected to current market context, cited company sources and its retained research file.
Organon & Co. trades as OGN on NYSE. Organon & Co. (OGN) has a latest verified close of 13.6, up 0.37%, dated 7 Aug 2026.
Open the chart, inspect attributed company evidence and continue into the fuller research file without losing this market context. Atlas files OGN under USA Stocks for browsing.
What changed for Organon & Co. today
Organon & Co. (OGN) kicked off 2026 with $1.46B in revenue and $146M in net income, but the pharmaceutical giant’s balance sheet tells a tighter story: $12.09B in liabilities versus $903M in equity, a cash hoard of $1.12B, and an inventory buildup of $1.37B that’s raising eyebrows. (source: SEC EDGAR 10-Q, period ending 2026-03-31)
OGN’s core business revolves around legacy drugs and medical devices, though recent filings hint at strategic turmoil. An July 17th 8-K disclosed a board-led review of ‘alternatives,’ including divestitures, while a June proxy statement revealed directors collecting phantom stock units-cash payouts tied to service termination, not performance. (source: SEC EDGAR 8-K, 2026-07-17; DEFM14A, 2026-06-17)
Free cash flow hit $188M (operating cash $225M minus $37M capex), but $9M in inventory growth and a 262.9M diluted share count suggest the company is expanding in ways that don’t always align with its polished narrative. (source: SEC EDGAR 10-Q, period ending 2026-03-31)
Chart-watchers note OGN’s lack of volume spikes despite the strategic review, with no evident institutional accumulation or distribution patterns in recent Form 4s. The stock’s quiet trading contrasts with the management desks drama buried in proxy filings. (source: SEC EDGAR 4 filings, 2026-06-15)
Key risks include execution on the medical device divestiture, debt refinancing pressures, and inventory liquidation risks. Catalysts hinge on Q2 results, regulatory approvals, and the outcome of the strategic review. (source: SEC EDGAR DEFA14A, 2026-07-17)
Sources & evidence · 10 links
This is the public answer layer. The full Atlas report adds the complete Market Wit archive, risk rail, catalyst map, final editor synthesis, PDF/CSV export, email delivery and saved history.
OGN technical readout
Directional bias up. Wilder ADX and ATR computed from Atlas approved daily OHLC through 2026-07-28. Indicators are descriptive statistics, not investment advice.
Open an Atlas research path on OGN
FreedomCore Atlas can expand this public profile into source-led research files with company snapshots, valuation context, filings and segment detail, source packs, and equity briefs. Each path keeps the underlying public sources visible.
Open Atlas workstation ->Keep OGN research in your Atlas archive
Free Atlas includes the public profile and one owned welcome research artifact after account setup. Atlas Pro adds up to 25 custom research runs a day, a 500-symbol watchlist, saved report versions, and eligible PDF, CSV, and email artifacts. Evidence holds still apply and never become an unverified download. £12/month founding price, locked for life. Research only; not investment advice.
Checking Atlas access...
OGN FAQ
What is Organon & Co. (OGN)?Organon & Co. (OGN) has a latest verified close of 13.6, up 0.37%, dated 7 Aug 2026. Use this page to check the price chart, company context, source-backed updates,...
Organon & Co. (OGN) has a latest verified close of 13.6, up 0.37%, dated 7 Aug 2026. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
What does Atlas show for OGN?Organon & Co. (OGN) has a latest verified close of 13.6, up 0.37%, dated 7 Aug 2026. It brings the latest available chart, company context, cited sources, risks and the...
Organon & Co. (OGN) has a latest verified close of 13.6, up 0.37%, dated 7 Aug 2026. It brings the latest available chart, company context, cited sources, risks and the route into the full Atlas research file together. Atlas files OGN under USA Stocks for browsing.
How often is the OGN page updated?The OGN public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the...
The OGN public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the freshness of the current market snapshot.
Which sources does Atlas use for OGN?The OGN file starts with SEC EDGAR filings, Nasdaq Trader and TradingView NYSE:OGN. SEC EDGAR provides the filing anchor for this issuer. The page separates verified...
The OGN file starts with SEC EDGAR filings, Nasdaq Trader and TradingView NYSE:OGN. SEC EDGAR provides the filing anchor for this issuer. The page separates verified market context from company evidence and shows open evidence gaps instead of filling them with assumptions.
Can Atlas run a full research brief on OGN?Yes. The workstation can open OGN, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Yes. The workstation can open OGN, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Is this OGN page investment advice?No. The OGN page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise...
No. The OGN page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise of returns.
Methodology
This profile is generated daily from public sources including SEC EDGAR (US-listed companies), NASDAQ Trader files, exchange listings, public macro/central-bank releases, CoinGecko crypto market files where relevant, and the TradingView global symbol catalog. Multi-model AI may assist drafting and review where configured, but sources remain the evidence rail; the chart is an Atlas static OHLC rail with a live TradingView link when verified bars are available; otherwise the page keeps the verified TradingView route as an explicit fallback.
Research only. Not investment advice. No brokerage execution. No guaranteed returns are promised or implied. FreedomCore does not provide personalised investment advice. Always consult a regulated financial advisor before making investment decisions.
Profile last updated: 2026-08-07. Browse FreedomCore Atlas research notes →